ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

Bush Tax Cut, Economic Slowdown Turn Up Heat On Budget Competition.

July 20, 2001

Centers See Trend To Integrate Control Service With Science

February 18, 1983

Grants & Contracts: NCI Workshop Informs Historically Black Institutions About Funding Process

October 10, 1997

California To Help Uninsured Get Prostate Cancer Therapy.

July 13, 2001

FDA Authority To Regulate Off-Label Promotion Challenged In Federal Court.

January 15, 2010

Roswell Park Wins $2.8 Million Grant

July 31, 2009